This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the DCs are routinely found within the tumor microenvironment, but their capacity for endogenous or therapeutically enhanced cross-presentation is not well characterized. In this study, we examined the tumor and lymph node DC cross-presentation of a nominal marker tumor antigen, hemagglutinin (HA), expressed by the murine mesothelioma tumor AB1-HA.
INTRODUCTION
Tumor antigens derived from solid tumors can be presented by host APCs to naïve
CD8
+ T cells in a process known as cross-presentation. Professional APCs, such as dendritic cells (DCs), play a key role in cross-presentation of tumor antigens in draining lymph nodes, a process that is critical for inducing tumor-specific cytotoxic T lymphocytes (CTLs) [1, 2] .
Several studies, including our own, have demonstrated the pivotal role of DCs in the crosspriming of tumor specific T-cell responses [3] [4] [5] [6] [7] . Furthermore, the most effective anti-tumor immunotherapies are associated with improving the response to cross-presented antigens [1, 2] .
When studying how DCs cross-present tumor antigens, most attention has focused on the priming events occurring in the tumor draining lymph node. However, there is evidence that DC cross-presentation within tissues is also an important component of memory and even naïve CD8 + T-cell responses [8, 9] . Additionally, it has been shown that tumorinfiltrating DCs (TiDCs) may be functionally impaired and/or unable to migrate to tumordraining lymph nodes (TDLNs) [10] .
In this study, we examined the capacity of TiDCs to cross-present cell-associated tumor antigen using the murine malignant mesothelioma line, AB1-HA, where influenza virus hemagglutinin (HA) is a membrane bound tumor neo-antigen. We characterized TiDCs in terms of their phenotype, antigen uptake and cross-presenting capacity during normal tumor growth and during regression following systemic cytotoxic chemotherapy with gemcitabine.
RESULTS

Tumor antigen-specific T-cell activation does not occur in the tumor microenvironment
In order to determine if tumor-specific CD8 + T cells recognize antigen presented in the tumor environment, we directly injected CFSE-labeled, HA-specific (CL4) T cells into the tumor site and measured their proliferation in the tumor as well as the spleen and tumor draining (TDLNs) and non-draining lymph nodes (NDLNs) (Fig. 1A) . Following intratumoral transfer, CFSE-labeled CL4 T cells made their way into the lymphatics and underwent robust proliferation in the TDLNs. The proportion of CL4 T cells proliferating in the draining axillary lymph node was greater than 60% at all time-points examined (Fig. 1B) . Similarly, the proportion of proliferating CL4 cells was greater than 60% in the draining inguinal lymph node by day 14 and as high as 85% by day 21. In contrast, CL4 T-cell proliferation in the NDLNs and spleen was less than 10% at all time points. Intriguingly, there were no proliferating CL4 cells in NDLN when cells were injected directly into the tumor site (Fig.   1B ). Proliferating CL4 T cells were never observed within the tumors at any time point throughout tumor growth (<5%), indicating that tumor antigen-specific T-cell activation does not occur in the tumor microenvironment either because of lack of antigen presentation or because of local suppression of proliferation.
Tumor-infiltrating DCs display a semi-mature phenotype
We hypothesized that the failure of transferred antigen-specific T cells to proliferate directly in the tumor site might be due to a failure of DCs within the tumor to restimulate infiltrating T cells, which has been termed 'post-licensing' [11] . For this reason, we first confirmed the presence of DCs within the tumor microenvironment using CD11c. DCs accounted for 1-3% of all cells in the tumor (Fig. 2A) . We found that tumors were predominantly infiltrated by DCs that were positive for the myeloid and dermal/interstitial DC marker CD11b, and negative for the plasmacytoid DC marker CD45RA, the resident lymphoid organ DC marker CD8α and the myeloid DC marker CD4 (Fig. 2B ). Importantly, TiDCs constitutively expressed MHC class I, MHC class II and the costimulatory molecules CD80 and CD86 (Fig 2C) , although they were able to further upregulate expression after overnight culture in the absence of specific additional stimulation ( Fig. 2D -E and Supporting Information Fig. 1 ). TiDC also expressed the positive and negative co-stimulatory molecules CD40, CD70, PD-L1/B7-H1 and PD-L2/B7-DC ( Fig. 2C and Supporting Information Fig. 1 was then critical to understand was whether the observed lack of cross-priming by TiDCs was due to lack of cross-presented antigen or a dominant inhibitory effect from negative costimulators.
TiDCs do not cross-present tumor antigen at the effector site
In order to further assess the direct T-cell priming potential of TiDCs, we purified them from tumors and co-cultured them with CL4 T cells, comparing responses to those by DCs purified from TDLNs in the same animals. Although purified DCs extracted from TDLNs induced robust CL4 proliferation, as previously demonstrated [14], TiDCs were not able to do this (Fig. 3A) . Importantly, the CL4 T cells exposed to TiDCs also showed no signs of activation in terms of CD69 expression or IFN-γ production (Fig. 3A) .
In order to determine if this failure of TiDCs to activate CL4 T cells was due to active inhibition, we added exogenous CL4 peptide to purified DCs -we anticipated that if inhibitory influences were dominant, the response to this peptide would be blunted relative to LNDCs (Fig 3B) . There was no significant difference in the ability of TiDCs to present HApeptide on their surface compared with normal LNDCs. Titration of HA peptide concentration revealed that the limit of sensitivity for both TiDCs and normal DCs was similar; at 10 pg/mL. These results strongly suggest that TiDCs have a defect in the antigen cross-presentation pathway, rather than being generically paralysed or being unable to costimulate T cells.
Ex vivo maturation does not rescue the capacity of TiDCs for cross-presentation
One possible explanation for these findings could be the semi-mature phenotype of TiDCs,
given that there is a close association between DC maturity and antigen processing and presentation [15] . Semi-mature DCs might be expected to take up antigen but fail to complete the processing of antigen and/or subsequent MHC loading. Therefore we extracted TiDCs, (Fig. 4A and B ).
These data suggest that TiDCs have an intrinsic defect in their capacity to process antigen that is not directly related to maturation.
TiDCs can take up and process exogenous cell-bound and protein antigen
Since the abrogated capacity of TiDCs to activate T cells could be restored by adding exogenous antigen, we next examined the capacity of TiDCs to take up cell-bound material, to determine if their poor cross-presentation at the tumor site was due to a failure to uptake antigens from tumor cellular material. We did this by co-culturing TiDCs with CFSE-labeled living, UV-irradiated or heat-killed tumor cells, respectively. We found that TiDCs could take up exogenous cell-bound material, as evidenced by acquisition of a positive CFSE signal after co-culture with labeled tumor cells (Fig. 5A ).
To determine if the block in DC cross-presentation was due to a reduced ability to process captured antigen, we next examined the capacity of TiDCs to take up and proteolytically cleave exogenous proteins, using the DQ-OVA system. This consists of the protein OVA This was more than fifteen times that observed in normal LN and splenic DCs which showed
MFIs of 80 and 63 at 37°C, respectively (Fig. 5B ), indicating that TiDCs are efficient at internalizing and processing soluble protein antigen.
Given that neither uptake nor processing were defective, we next examined the capacity of 
The reduced capacity of TiDCs to cross-present antigen is reversed by chemotherapy
Given the potential importance of cross-presentation by TiDCs in restimulating TILs, and the block in this process described above, we reasoned that immunogenic chemotherapies which induce strong CD8-dependent effector responses in vivo might reverse this block. We have previously shown that immunogenic anti-cancer chemotherapy with the cytotoxic drug, gemcitabine, can lead to an increase in HA-specific CD8 + T cells within the tumor tissue [5] .
Given this, we examined the effect of systemic gemcitabine chemotherapy on TiDC crosspresentation capacity. Whereas TiDCs from saline treated mice were defective in their capacity to induce CL4 T-cell proliferation, TiDCs enriched from gemcitabine treated animals spontaneously induced proliferation of CL4 T cells (Fig. 6A ). Furthermore, this proliferation was associated with increased IFN-γ production ( (Fig. 6D ). In addition, gemcitabine did not affect the ability of TiDCs to take up a particulate antigen at the tumor site ( Fig 6E) . Thus, the level of tumor antigen cross presentation observed following gemcitabine therapy is not due to changes in TiDC subsets, maturation state or antigen capture. These results support the idea that gemcitabine increases the cross-presentation of tumor antigens by tumor-infiltrating dendritic cells and increases our understanding of why some chemotherapy drugs are immunogenic and others are not [17, 18] .
DISCUSSION
When studying how DCs cross-present tumor antigens, most attention has focused on priming events in the local draining lymph node. However, there is some evidence that crosspresentation within tissues may also be an important component of CD8 + T-cell responses contributing to effector function or tolerance within the tumor [19, 20] . Therefore in this study, we aimed to characterize the immunogenic potential and in particular the crosspresenting capacity of TiDCs. We found several key features of TiDC to be defective when compared to LNDCs and importantly, showed how these defects could be reversed.
Firstly, our data show that tumor antigen-specific T-cell activation does not occur in Secondly, although TiDCs had an inhibited potential to activate antigen-specific Tcells, the fact that this could be fully restored when exogenous MHC class I peptide was added indicated that the cross-presentation pathway was hampered rather than T-cell priming.
Our findings that spontaneous maturation occurs upon ex vivo culture prior to co-incubation with antigen-specific T cells but addition of LPS, polyI:C, IFN- or anti-CD40 agonist antibody to ex vivo TiDCs could not overcome their inability to cross-present tumor antigen shows that the defect was not one of maturation. In a similar study, DCs isolated from B16 melanomas were previously shown to be defective in their ability to induce proliferation of Following our observation that TiDCs have poor T-cell stimulatory potential and our finding that the uptake and proteolytic cleavage of exogenous antigen is normal, we conclude that the failure to cross-prime is distal to antigen uptake and processing. As TiDCs were able to cross-present exogenous HA protein to specific T cells, albeit with reduced efficiency, the problem may temporally occur after the processes of uptake and proteolytic cleavage, in the MHC class I-loading pathway. The failure of cross-presentation of cell-derived tumor antigens combined with an intact ability to process and cross-present soluble tumor antigen is consistent with a defect in the processing pathway between intracellular compartments and the cytoplasm. Future studies will need to address where this block occurs, determine which molecular events create the block and how they can be overcome.
Lastly, we tested whether gemcitabine, a chemotherapy agent known to be would be necessary to deplete DCs in a temporal and spatially specific manner, i.e. in the tumor during the effector phase. Future studies will further address this question.
In conclusion, the data supports a model where gemcitabine chemotherapy increases cross-presentation of tumor antigens by tumor resident DCs to cross-arm tumor-infiltrating CD8 + T cells for full effector function; a process which can be further exploited in the immunotherapy of cancer. were purchased from Polysciences (Warrington, PA, US). 
Materials and methods
Animals
Tumor cells and inoculation
AB1-HA (H-
Gemcitabine treatment
For some experiments, mice were treated with gemcitabine (Gemzar, Lilly) 120 mg/kg intraperitoneally (i.p.) or saline, once on day 19 after tumor inoculation. At day 21 tumor tissue was pooled from 9 mice and DCs were enriched and tested for their T-cell stimulatory potential as described below.
Collagenase-DNase digestion of lymph nodes and tumor tissue
Lymph nodes and tumor tissue were digested with 1 mg/mL collagenase type II (Worthington Proliferation was analyzed by CFSE dilution using flow cytometry (FACS Calibur, BD Biosciences).
In vivo antigen presentation 'Lyons-Parish' Assay
A total of 1-2x10 7 CFSE-labeled HA-specific CL4 TCR-transgenic splenocytes were injected intratumorally (i.t.) into recipient mice. TDLNs and tumor tissue were harvested 3 days following adoptive transfer and counter-stained with anti-CD8-PECy5.5 (53-6.7, BD Biosciences) prior to flow cytometry (FACS Calibur, BD Biosciences).
DC and tumor cell co-culture
Lymph nodes, spleens and tumor tissue were harvested, single cell suspensions generated by enzymatic digestion and DCs isolated as described above. CFSE-labelled AB1-HA tumor cells were left untreated, subjected to UV light for 10 min followed by 2 h recovery at 37C, or heat killed by incubation at 65C for 1 hour. DCs and tumor cells were cultured alone or
were mixed together at a 1:1 ratio and incubated at 37C for 24 or 0 h then washed and counter stained with anti-CD11c-Allophycocyanin or hamster IgG-Allophycyanin isotype control. The amount of CFSE label acquired by DCs following 24 h co-culture was determined by flow cytometry.
In vitro uptake of DQ-OVA
Lymph nodes, spleens and tumor tissue were harvested, single cell suspensions generated by enzymatic digestion and DCs isolated as described above. DC preparations from each tissue were incubated with 100 g/mL DQ-OVA for 2 h at 37C or 4C, washed extensively and stained for CD11c expression prior to FACS acquisition (BD FACS Calibur). The amount of in the green fluorescence (FL-1) channel compared to background at 4C.
Incubation with HA peptide or protein
Purified DCs were resuspended at 1x10 6 per mL in R10 and incubated at 37C with the desired concentration of HA peptide or recombinant HA protein (Protein Sciences Corporation, Meriden, CT, USA) for 30 min or 2 h, respectively. Cells were then washed three times with warm R10 through an FCS cushion and cell number determined by trypan blue exclusion.
In vivo uptake of Fluoresbrite microspheres
AB1-HA tumor-bearing mice were injected i.t. with 2x10 7 Fluoresbrite YG microbeads (Polysciences, Warrington, PA, US) in 20 uL of saline. Tumors were harvested 24 h later and single cell suspension generated by enzymatic digestion as discussed above. Cells were stained with anti-CD11c-Allophycocyanin (N418, BioLegend, San Diego, CA, US) and then analyzed by flow cytometry.
Statistical Analysis
Statistical significance was calculated using GraphPad PRISM (San Diego, CA). Statistical significance between individual treatment groups was determined using the student's t-test or 
